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https://doi.org/10.1016/j.celrep.2018.02.038SUMMARY
Despite its low cellular abundance, phosphotyrosine
(pTyr) regulates numerous cell signaling pathways
in health and disease. We applied comprehensive
phosphoproteomics to unravel differential regulators
of receptor tyrosine kinase (RTK)-initiated signaling
networks upon activation by Pdgf-bb, Fgf-2, or
Igf-1 and identified more than 40,000 phosphoryla-
tion sites, including many phosphotyrosine sites
without additional enrichment. The analysis revealed
RTK-specific regulation of hundreds of pTyr sites on
key signaling molecules. We found the tyrosine
phosphatase Shp-2 to be the master regulator of
Pdgfr pTyr signaling. Application of a recently intro-
duced allosteric Shp-2 inhibitor revealed global regu-
lation of the Pdgf-dependent tyrosine phosphopro-
teome, which significantly impaired cell migration.
In addition, we present a list of hundreds of Shp-2-
dependent targets and putative substrates, including
Rasa1 and Cortactin with increased pTyr and Gab1
and Erk1/2 with decreased pTyr. Our study demon-
strates that large-scale quantitative phosphoproteo-
mics can precisely dissect tightly regulated kinase-
phosphatase signaling networks.
INTRODUCTION
Withadvances inproteomic technologies, it ispossible tocompre-
hensively analyze human cell proteomes on par with next-genera-
tion genomic sequencing (Bekker-Jensen et al., 2017; Kim et al.,
2014). However, routine analysis of post-translational modifica-
tions (PTMs) remains challengingdue to their generally lowcellular
abundance and dynamic nature. Above all, site-specific protein
phosphorylation on serine, threonine, and tyrosine residues is of
great importance in eukaryotic cells due to their crucial role in
rapidly regulating essentially all intracellular signaling networks2784 Cell Reports 22, 2784–2796, March 6, 2018 ª 2018 The Author
This is an open access article under the CC BY-NC-ND license (http://(Olsen et al., 2006). Protein phosphorylation is tightly regulated
in healthy cells by the opposing action of protein kinases and
phosphatases, which are the enzymes that write and erase this
modification, respectively (Ubersax and Ferrell, 2007). Phospho-
tyrosine (pTyr) in particular remains elusive in its detection due to
its highly transient and regulatory nature, which leads to overall
lower phosphorylation stoichiometry and cellular abundance rela-
tive to its phosphoserine (pSer) and phosphothreonine (pThr)
counterparts, which are readily observed in global phosphopro-
teomic experiments (Sharma et al., 2014). As a result, many
large-scale cell signaling studies may inadvertently omit pTyr
analysis and therebyoverlooka vital layer of information regulating
cell signaling and outcome. Obtaining greater molecular under-
standing of pTyr-driven signaling (alongside pSer and pThr) is
the foundation forunderstandingsignalingnetworkssuchas those
initiated by receptor tyrosine kinases (RTKs), which are able to
receive extracellular signals and relay them inside the cell plasma
membrane, ultimately affecting cell fate, suchas survival, differen-
tiation, proliferation, and migration (Lemmon and Schlessinger,
2010). Consequently, RTKs and proteins involved in their down-
stream signaling tend to be highly oncogenic and thus the fore-
most drug targets in various cancers (Koytiger et al., 2013).
To address this challenge, we developed a streamlined phos-
phoproteomic framework based on high-pH reversed-phase
chromatography (Wang et al., 2011) with automatic fraction
concatenation followed by sensitive liquid chromatography-tan-
dem mass spectrometry (LC-MS/MS) analysis. This enabled
global detection of pSer, pThr, and pTyr sites in a single analysis
without the need for phosphotyrosine-specific antibody pull-
downs. By primarily using phosphotyrosine site regulation as
the proxy of early signaling events, the initial analysis allowed
us to observe distinct activation of numerous signaling path-
ways with RTK ligand treatment. We found platelet-derived
growth factor receptor (Pdgfr) (a and b subunits) to be a potent
activator of most downstream signaling pathways. We observed
that Shp-2 acts as a master regulator of the mitogen-acti-
vated protein kinase/extracellular-regulated kinase (Mapk/Erk)
pathway for Pdgfr, and through the application of an allosteric
Shp-2 phosphatase inhibitor, in combination with quantitatives.
creativecommons.org/licenses/by-nc-nd/4.0/).
AB
C
Figure 1. Experimental Design and Phosphoproteomic Workflow Allows Comprehensive Analysis of Phosphorylation Sites
(A) NIH/3T3 cells were stimulated with three RTK ligands (Pdgf-bb, Fgf-2, and Igf-1) at the indicated time points, followed by rapid lysis, protein extraction, and
digestion into tryptic peptides (see Materials and Methods).
(B) Peptides were automatically peptide fractionated and concatenated using high-pH reversed-phase chromatography in batch mode (AUTOCON) (Movie S1).
For phosphoproteomic analysis, fractionated peptides were enriched using TiO2 metal oxide affinity enrichment. Resulting phosphopeptides were analyzed by
LC-MS/MS, where a highly sensitive MS scanning method was used and database search analysis of raw data was performed using MaxQuant as described in
Materials and Methods.
(C) Overview of data analysis is shown; details are given in Materials and Methods. For phosphoproteomics, data were filtered and normalized to ensure fair
comparison across all samples. The resulting phosphoproteome datasets resulted in a large number of phosphosites, including phosphotyrosine (pTyr) sites.
Cells stimulated with Pdgf-bb showed the largest number of regulated pTyr sites (which were also measured in control, non-stimulated samples).
See also Figures S1 and S2 and Table S1.phosphoproteomics, our analysis revealed global rewiring of the
tyrosine phosphoproteome in a Pdgf-bb-dependentmanner. This
dataset also provides a list of putative Shp-2 substrates, which
include proteins regulating downstream RTK signaling pathways
important for cellular outcomes such as proliferation and migra-
tion. Collectively, our investigation may increase our mechanistic
insight into RTK signal propagation and phosphatase action.
RESULTS
Antibody-Free Screen Enables Unbiased In-Depth
Identification of Phosphorylation Sites
We employed an optimized phosphoproteomic workflow based
on label-free quantitation to unravel regulators of downstream
RTK signaling networks mediated by three activated RTKs. Weinvestigated the global phosphosignaling response initiated by
three RTKs in mice fibroblast NIH/3T3 cells after stimulation
with their respective canonical ligands: platelet-derived growth
factor beta receptor (Pdgf-bb ligand), fibroblast growth factor
receptor 1 (Fgf-2 ligand), and insulin-like growth factor 1 receptor
(Igf-1 ligand), which were selected due to their abundance (Fig-
ure S1A). Their ligands induced a downstream phosphorylation
response, evidenced by the activation and phosphorylation of
Mapk/Erk (Figure S1B). We performed time-resolved quantita-
tive phosphoproteomics to study the dynamic processes under-
lying the activation of RTK signal transduction. Samples were
collected after 3 and 15 min of ligand stimulation, followed by
efficient lysis and protein extraction, cysteine reduction, and
alkylation in one step as previously reported (Figure 1A) (Jer-
sie-Christensen et al., 2016; Poulsen et al., 2013).Cell Reports 22, 2784–2796, March 6, 2018 2785
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Figure 2. Phosphoproteomic Analysis Discriminates Ligand-Induced Phosphorylation of Tyrosine Sites
Tyrosine site phosphorylation intensities are visualized in a ternary plot to highlight the differential phosphorylation patterns induced upon Pdgf-bb, Fgf-2, and
Igf-1 stimulation. Each dot represents one unique pTyr site. Both color coding and mapping are based on the fractional intensities observed for each pTyr site
upon the different ligand stimulations. A maximum intensity between 3 and 15 min was used for individual sites. Corners indicate pTyr sites specifically
responsive upon Pdgf-bb, Fgf-2, or Igf-1 stimulation. Tyrosine sites plotted in the center are equally phosphorylated by the three ligands. See also Figure S3 and
Table S1.We have previously demonstrated an efficient strategy for
offline fractionation of phosphopeptides based on high-pH
fractionation, which enabled us to identify a large number of
tyrosine-phosphorylated peptides, similar to what is typically
observed with the extensive use of pan-anti-pTyr antibodies
(Batth et al., 2014). To establish a streamlined and comprehen-
sive phosphoproteomic workflow, we automated the offline
fractionation and concatenation (AUTOCON) steps before
mass spectrometry (MS) analysis (Movie S1), which allowed us
to process samples in batch mode and increase our throughput
and reproducibility (Figure 1B). The phosphoproteomic workflow
enabled the identification of 41,289 phosphorylation sites
covering more than 7,000 phosphoproteins. We applied a strict
quality filter. The resultingphosphosite intensities covered a large
dynamic range, more than 6 orders of magnitude in each exper-
iment, and29,027phosphorylation siteswerequantifiable across
conditions (Table S1). Analysis of the phosphorylated amino acid
distribution showed that 84% of phosphorylation sites were on
serine, whereas the 13% were threonine phosphorylation sites
(Figure 1C). In addition, 851 (3%) of the total quantifiable phos-
phorylation sites belonged to tyrosine-containing peptides (Fig-
ure 1C), pinpointing amajor strength of our workflow in achieving
high pTyr coverage without pretreating cells with pervanadate.
Phosphotyrosine sites were roughly 2-fold lower in abundance
compared to pSer and pThr (Figure S2A), which underscores the
general challenges in detecting them byMS. Our workflow led to2786 Cell Reports 22, 2784–2796, March 6, 2018an efficient accumulation of phosphotyrosine-containing pep-
tides over the 12 high-pH fractions (Figure S2B), resulting in
the identification of pTyr sites on more than 500 proteins
enriched for RTK signaling, kinase activity, and protein binding
and inclined to be localized at the plasma membrane and cyto-
plasm (Figure S2C). These data demonstrate the streamlined
and comprehensive phosphoproteomic workflow encompass-
ing serine, threonine, and pTyr.
Global Analysis of pTyr Sites
We analyzed the ligand-induced distribution of the quantified
pTyr sites to gain insights into pTyr signaling upon differential
RTK stimulation. Specifically, the proportional response in the
pTyr site intensities (ternary plot) (Figure 2) distinguished the
stimulating condition under which the sites are distributed rela-
tive to one another. Activated Pdgfr was the most potent regu-
lator of pTyr sites when compared to Fgfr1 and Igf1r, as shown
by a large cluster of pTyr sites at the top of the ternary plot, indi-
cating higher relative response. Density estimation of all phos-
phorylation sites under the three RTK stimulation conditions
indicated that this phenomenon was not global and was limited
only to pTyr, because similar distributions were not observed
for pSer and pThr sites (Figure S3). We found 21 pTyr sites on
the cytoplasmic tail near the C terminus of Pdgfr-a (11) and
Pdgfr-b (10) subunits (Heldin and Lennartsson, 2013) to be
exclusively detected upon Pdgf-bb stimulation. In addition, we
A B
Figure 3. Phosphoproteomic Analysis Reveals Differential Ligand-Induced Activation of Signaling Pathways
(A) Dynamic profiles of site phosphorylation on proteins involved in different signaling pathways upon Pdgf-bb, Fgf-2, and Igf-1 stimulation are shown. The size of
each dot is the mean of the site phosphorylation intensities among replicates, which were identified in each of the seven conditions. Bigger correlates with a
strong induction of phosphorylation for the indicated site and condition. Relativemaximum intensity values for each site were used to proportionally normalize the
global site phosphorylation dynamic profile. Minimum values were set to 0.01 (on a scale to 1) for representative purposes.
(B) Lysates from NIH/3T3 cells stimulated with Pdgf-bb, Fgf-2, and Igf-1 for the indicated time points were immunoblotted as indicated to validate the differential
dynamic profile. Tubulin was used as loading control.
*Confirmed by western blot, **antibody cross-reaction for the activated form of Pdgfr-b as indicated by the manufacturer. See also Figure S4 and Table S1.found six pTyr sites on Fgfr1 and fibroblast growth factor recep-
tor 2 (Fgfr2) when stimulated with Fgf-2 (Figure 2; Table S1) (Fur-
dui et al., 2006). Sites on canonical adaptor molecules such as
Grb2 (pY209), Frs2 (pY306), and Irs2 (pY671) were also identi-
fied, indicating their preferential binding to activated Pdgfr,
Fgfr1, and Igf1r, respectively (Figure 2). The analysis demon-
strated the sensitivity of our workflow for screening pTyr sites
without the need for pan-anti-pTyr antibody-based enrichment
and comparable to state-of-the-art, antibody-based, phospho-
tyrosine-focused studies (Abe et al., 2017). The number of tyro-
sine sites reported in this study were roughly 6-fold higher than
those reported with the EasyPhos method, which was used to
study insulin signaling (another RTK) in vivo over several time
points (Humphrey et al., 2015).
Phosphorylation Site Dynamics Reveal Preferentially
Activated Signaling Pathways
The distinct activation of pTyr sites upon ligand stimulation
suggests that the response initiated by each ligand-RTK pairdifferentially regulate downstream signaling pathways (Franca-
villa et al., 2016). We visualized their temporal changes as quan-
titative dot blots (Figure 3A) and validated our results by western
blot analysis and quantification (Figure 3B; Figure S4). We found
Pdgf-bb and Fgf-2 stimulation induced phosphorylation of the
activation loop residues pT203 and pY205 on Mapk/Erk1 (Fig-
ure 3). However, we observed that Pdgf-bb exclusively activated
Pik3/Akt (i.e., Pik3ca pY508 and Akt1 pS473), as well as Jak/Stat
(i.e., Stat3 pY705) and Plc-g (i.e., Plcg1 pY783) pathways.
Conversely, Fgf-2-treated cells pinpointed a preferential phos-
phorylation of Y614 and Y615 on focal adhesion kinase 1 (Ptb2
or Fak1) (Figure 3B). Surprisingly, Pdgf-bb-stimulated cells dis-
played a reduction in the basal level of phosphorylation of
Y614 and Y615 on Fak1 at both time points despite the relatively
high pTyr response seen upon Pdgf-bb stimulation. Because
Igf-1 stimulation did not significantly induce activation of major
signaling pathways, the remainder of this study was focused
on the comparative analysis of the signaling responsesmediated
by Pdgfr and Fgfr1 activation. Collectively, these data supportCell Reports 22, 2784–2796, March 6, 2018 2787
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Figure 4. Pdgf-bb-Induced Activation of Shp-2 Affects Y614 and
Y615 Phosphorylation on Fak1
(A) Lysates from cells stimulated with Pdgf-bb, Fgf-2, and Igf-1 for 3 min were
immunoblotted as indicated. Bands related to Fak1 phosphorylation are
shown after a longer exposure to emphasize the differences across the con-
ditions.
(B) Lysates from cells stimulated with Pdgf-bb, Fgf-2, and Igf-1 for 3 min were
analyzed by immunoblotting with the designated antibodies. When indicated,
cells were treated with SHP099 for 30 min before ligand stimulation.
Vinculin was used as loading control. SHP099, Shp-2 inhibitor. See also Fig-
ure S5.the comprehensive phosphorylation workflow to investigate
dynamic RTK signaling pathways.
Fak1 Dephosphorylation Correlates with Pdgfr-
Dependent Shp-2 Activation
We hypothesized the presence of a Pdgf-bb-dependent regula-
tory mechanism leading to Y614 and Y615 dephosphorylation
on Fak1. We speculated that activated tyrosine phosphatases
might play a role in mediating this and confirmed the possibility
with global inhibition of tyrosine phosphatase activity with perva-
nadate (Figure S5A). Thus, we examined phosphatases exclu-
sively tyrosine phosphorylated upon Pdgfr activation. We found
protein tyrosine phosphate non-receptor type 11 (Shp-2 en-
coded by PTPN11) to be a putative candidate, because it
displayed pronounced (a more than 60-fold increase) pTyr at
positions Y546 and Y584, sites known to positively regulate
Shp-2 enzymatic activity (Figures 3A and 4A; Table S1) (Zhang
et al., 2015). We reasoned that Pdgfr-mediated activation of2788 Cell Reports 22, 2784–2796, March 6, 2018Shp-2 might be responsible for Y614 and Y615 dephosphoryla-
tion on Fak1 (Man˜es et al., 1999). We tested the impact of Shp-2
inhibition on Fak1 Y614 and Y615 dephosphorylation by a newly
developed allosteric Shp-2 inhibitor SHP099 (Chen et al., 2016)
and observed that Shp-2 inhibition in Pdgf-bb-treated cells led
to increased Y614 and Y615 phosphorylation on Fak1 (Fig-
ure 4B). Although an increase of phosphorylation on Fak1 was
also observed upon Fgf-2 treatment in the presence of the inhib-
itor, it was less pronounced relative to Pdgf-bb stimulation (with
SHP099), which inversed the phosphorylation dynamics on
these two Fak1 pTyr sites. The results indicate that Shp-2 is an
active player in Pdgfr signaling and directly affects Fak1
phosphorylation.
Shp-2 Regulates the Global Pdgfr Phosphoproteome
Landscape
We characterized the overall impact of Shp-2 activation in Pdgfr-
mediated phosphosignaling response with a stable isotope
labeling by amino acids in cell culture (SILAC)-based approach,
in combination with phosphotyrosine peptide pull-down (Fig-
ure 5; Figure S6A) (Ong et al., 2002). Our findings revealed global
changes in phosphorylation upon Pdgfr activation in Shp-2-in-
hibited cells (Figure S6B). Approximately 20% (1,428) of 6,884
quantified phosphorylation sites were statistically regulated
more than 2-fold in the presence of SHP099 with Pdgf-bb
stimulation (based on Student’s t test, p < 0.05) (Table S2).
Relative to serine and threonine phosphorylation sites, pTyr
was mostly upregulated with Pdgf-bb stimulation, alongside
Shp-2 inhibitor (Figures S6B–S6E). Phosphotyrosine sites that
were R2-fold upregulated (p < 0.05 based on Student’s t test)
upon Pdgf-bb stimulation in the presence of SHP099 were
deemed Shp-2-putative substrates (Table S2).
Our results revealed the negative regulation of Fak signaling
(pY614/615) by Shp-2/Pdgfr was reversed in the presence of
SHP099. Furthermore, pY421 on cortactin (Cttn), a known
important substrate of Fak signaling that is suggested to modu-
late cytoskeletal organization and cell motility, displayed dra-
matic increase in phosphorylation upon Pdgf-bb stimulation
when cotreated with SHP099 (Figure S7A; Table S2) (Tomar
et al., 2012). We confirmed the dynamics of this key site on
Cttn by using a site-specific antibody for pY421, which was
abolished in the presence of Fak1 inhibitor PF-562271 (Fig-
ure 5B). In addition, Shp-2 and Fak1 were found to be constitu-
tively associated and recruited to the Pdgfr signaling complex
upon Pdgf-bb stimulation (Figures S7B and S7C).
Moreover, the results confirmed the specificity of Shp-2 inhibi-
tor (SHP099) in inhibiting the Mapk/Erk pathway activation via
significant downregulation of phospho-Erk1/2 activation sites
pY185/205 (Figure 5) (Chen et al., 2016). As a consequence, we
identifiedmanyof thedownregulatedpSer sites that arepredicted
Erk1/2 substrates (Table S2). However, other signaling pathways
were largely unaffected by Shp-2 inhibition, as determined by
phosphorylation of prominent activation sites on Akt (pS473)
and Stat (pY705), as well as pTyr sites on Plcg1 and Pik3c, which
had unchanged or increased phosphorylation (Table S2). Our
dataset demonstrates global upregulation of most phosphotyro-
sine signaling pathways by Shp-2 inhibition but accompanied
by deactivation of the Mapk/Erk signaling cascade.
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(A) Volcano plot of SILAC phosphotyrosine site (class I) ratios after 15min of Pdgf-bb stimulation with and without Shp-2 inhibitor SHP099 at a false discovery rate
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(B) Indirect regulation of cortactin phosphorylation at pY421 (target of Fak1) is confirmed via Fak1 inhibition with inhibitor PF-562271.
(C) Interaction of Gab1 and Rasa1 with Pdgfr-b via immunoprecipitation shows decreased receptor-adaptor interaction of Gab1 with Shp-2 inhibition when Pdgfr
is activated with Pdgf-bb stimulation. The opposite trend is observed for Rasa1, where an increase in interaction of these two proteins is observed.
See also Figures S6 and S7 and Table S2.Shp-2 Regulates the Interaction of Pdgfr with Signaling
Proteins
Some of the most significantly upregulated pTyr sites with Shp-2
inhibition, alongside Pdgf-bb stimulation, were found on proteins
harboring guanosine triphosphatase (GTPase)-activating protein(GAP) domains (Figure 5A). We found significantly upregulated
pTyr sites on GAP proteins spanning several GTPase families,
such as Rasa1, Arhgap12, and Tbc1d10a (Figure 5A; Table S2).
Increased levelsofRasa1, aRas-specificGTPase,wereobserved
to coimmunoprecipitate with Pdgfr upon Shp-2 inhibition andCell Reports 22, 2784–2796, March 6, 2018 2789
Gfp-Gab1 DAPI Merge
S
H
P
09
9
S
H
P
09
9
D
M
S
O
D
M
S
O
+P
dg
f-β
β
M
oc
k
+Pdgf-ββ
5 μm
A
CB
DM
SO
 S
HP
09
9
DM
SO
SH
P0
99
0
20
40
60
80
100
Gfp-Gab1 plasma membrane localization
%
 c
el
ls
 w
ith
 P
.M
 lo
ca
liz
ed
 G
fp
-G
ab
1
n.s.
p = 0.0015
p = 0.0028
Mock
Pdgf-ββ
P
P
P
P
P
P
Grb2
Gab1
Shp2
Gab1
Rasa1
Grb2
Gab1
Shp2
Gab1
Rasa1
SHP099
Active
Erk1/2
Inactive
Erk1/2
(legend on next page)
2790 Cell Reports 22, 2784–2796, March 6, 2018
Pdgf-bb stimulation (Figure 5C). pTyr on the crucial adaptor pro-
tein Grb2-associated binder 1 (Gab1) at pY628 was significantly
downregulated, alongside markers of Erk/Mapk pathway activa-
tion (via phospho-Erk1/2 sites pY185/205) in the presence of
Shp-2 inhibitor. Gab1-induced Erk activation after Met receptor
activation haspreviously been shown to dependonShp-2 activity
(Maroun et al., 2003). Therefore, we hypothesized that this could
be equivalent in Pdgfr-activated cells. We found Gab1 to signifi-
cantly decrease its interaction with Pdgfr in the presence of
Shp-2 inhibition (Figure 5C). Because Gab1 is known to be tar-
geted to the plasma membrane upon RTK stimulation (Chang
et al., 2015), we observed an accumulation of Gab1 to the plasma
membrane upon Pdgf-bb stimulation (Figure 6). However, there
was a significant reduction of Gab1 recruitment to the cellular
plasma membrane after Pdgf-bb stimulation in the presence of
SHP099 (Figure 6B). The results indicate dynamic Shp-2-depen-
dent regulation of key proteins, leading to changes in protein
localization and pathway activation (Figure 6C).
Shp-2 Affects Ligand-Dependent Cellular Outcomes
Wenext sought todetermine the impactofPdgfr- andFgfr1-medi-
ated signaling on cellular outcomes. Pdgf-bb-induced cell migra-
tion and proliferation were both affected by Shp-2 inhibition,
whereas Fgf-2-induced cellular responses were not (Figure 7).
Specifically, Shp-2 inhibition, alongside Pdgf-bb costimulation,
of cells significantly reduced the rate at which cells migrated,
while thiswas not observedwith Fgf-2 stimulation in the presence
of inhibitor (Figures 7A an 7B). The opposite trend was observed
for cell proliferation in cells coexposed to SHP099 and Pdgf-bb,
displaying slightly higher proliferation rates comparable to Fgf-2
treatment. Conversely, SHP099 treatment, in combination with
Fgf-2 stimulation, failed to affect the proliferation rate significantly
(Figure 7C). Collectively, the results indicate an active role for
Shp-2 in dictating Pdgf-bb-mediated cellular migration, but not
Fgf-2-dependent signaling and cellular responses.
DISCUSSION
Tight regulation of the interplay among multiple cell signaling
networks activated by RTKs is necessary to ensure normal
cellular function. Identifying signaling proteins and quantifying
their phosphorylation status directly by phosphoproteomics is
emerging as an alternative to indirect approaches based on
inferring cellular signaling network rewiring via genomic and tran-
scriptomic studies (Yaffe, 2013). In this work, we demonstrate
proof-of-principle of detecting and quantifying phosphotyro-
sine-containing peptides simultaneously with pSer and pThr
without additional affinity purification via cocktails of pan-anti-
pTyr antibodies. This foundation proved to be essential in theFigure 6. Immunofluorescence Imaging of Gfp-Gab1 Shows Treatmen
(A) Representative immunofluorescent cell images of Gfp-Gab1 cell nucleus with D
cells were cooled to 4C for 30 min before stimulation with Pdgf-bb.
(B) Quantitation of Gab1 localization was determined by manually counting th
biological replicates (n = 4) performed on two separate days were used to dete
coverslip. Between 11 and 48 cells were counted for each coverslip. Error bars r
(C) Schematic model of the role of Shp-2 in Pdgfr signaling is illustrated. Inhibitio
arrows) and the reverse for Gab1.global investigation of endogenous RTK signaling and activation
in murine fibroblast cells. The dataset will serve as a valuable
resource for further follow-up of novel proteins and phosphoryla-
tion sites that may be involved in regulating downstream
RTK response. Because Pdgfr is a crucial RTK implicated in
numerous cancers and a prominent target for therapy, under-
standing its downstream signaling components could provide
invaluable insight for treatment.
We conceptually demonstrated the potential of an antibody-
free phosphoproteomic workflow by distinguishing the regula-
tion of key downstream elements in Pdgfr signaling, such as
Shp-2, Fak1, and Gab1, via pTyr. Although the relationships
among these individual molecules have been well investigated
as single- or two-component systems, our analysis pinpointed
the interdepended regulation of each of these molecules simul-
taneously in an unbiased manner. The results highlight Shp-2
as a master regulator of downstream Pdgfr signaling while
havingmodest to no influence on Fgfr signaling. Despite reduced
cell migration upon Shp-2 inhibition, alongside Pdgfr activation,
cell proliferationwas surprisingly largely unaffected in our biolog-
ical system. This could indicate different mechanisms of Mapk/
Erk activation via activated Fgfr1 through distinct adaptor pro-
teins such as Frs2. For instance, our results suggest that active
Shp-2 is required for Gab1 recruitment to Pdgfr and the plasma
membrane, which leads to full activation of the Erk/Mapk
pathway. pTyr of Gab1 at pY628 has been suggested as a poten-
tial docking site for Shp-2 (Chan et al., 2010; Cunnick et al.,
2001); however, it is possible that Shp-2 inhibition results in
competitive Pdgfr interaction with an alternative protein super-
seding Gab1. It is conceivable that uncontrolled pTyr leads to
the recruitment and localization of proteins and molecules that
inhibit Erk1/2 activation. The significant increase in pTyr on
several GAPs implies a crucial role in deactivating guanosine
triphosphate (GTP)-bound Ras (active state), thus eliminating
downstream activation of Erk via Ras/Raf/Mek. Unexpectedly,
our results also indicate a potential role for GAPs, which have
yet to be implicated with RTK signaling. Whether this results in
reduced Gab1 pTyr and, as a consequence, reduced plasma
membrane localization still needs to be determined. It is also
plausible that additional molecular mechanisms and proteins
could be involved in a synergistic or cumulative manner, leading
to Mapk/Erk inhibition. Nonetheless, our dataset opens up the
avenue for further examination of the role of several proteins
that may regulate additional RTK signaling pathways in a similar
manner and could serve as novel therapeutic targets.
The importance of phosphotyrosine signaling in health and
disease is unquestionable, but global and unbiased tyrosine
phosphoproteomic investigations have so far been limited due
to its low cellular abundance. We demonstrated the benefits oft-Dependent Cellular Localization
API staining of NIH/3T3 cells under different treatment conditions. For imaging,
e number of cells, which displayed Gfp-Gab1 membrane localization. Four
rmine statistical significance. Each biological replicate represents a different
epresent SD, and the p value was determined by unpaired two-tailed t test.
n of Shp-2 results in increased localization of Rasa1 to Pdgfr (as indicated by
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Figure 7. Shp-2 Is Involved in Pdgf-bb-Dependent Cellular Responses
(A) Cell migration upon ligand stimulation after 24 hr was detected by wound healing assay. Representative wound closure images of the scratch cross-sectional
areas from three experiments are shown.
(B) Cell migration was calculated as described inMaterials andMethods. Values are normalized to their respective 0 hr time point and presented asmeans ±SEM
of three independent experiments.
(C) Cell proliferation assay upon ligand stimulation after 72 and 96 hr. Black lines represent control cells. Results are expressed as fold induction (means ± SEM)
from three independent experiments.
SHP099, Shp-2 inhibitor. *p < 0.05 (Student’s two-tailed t test).a global phosphoproteomic workflow for elucidating differential
endogenous RTK signaling networks and expect similar work-
flows to be routinely applied directly toward analyzing signaling
in tumor and cancer tissues. This provides opportunities to iden-
tify new biomarkers and drug candidates. As such, we hope that
our datasets will serve as a beneficial foundation for further vali-
dation and mechanistic elucidation of several novel proteins that
could be implicated in modulating downstream RTK signaling.2792 Cell Reports 22, 2784–2796, March 6, 2018EXPERIMENTAL PROCEDURES
Reagents
The following commercial reagents were used: Fgf-2, Pdgf-bb, and Igf-I
(PeproTech); DMSO (Sigma-Aldrich); Shp-2 inhibitor SHP099 (Xcessbio);
Fak1 inhibitor PF-562271 (Selleckchem); and Mek inhibitor U0126 (Cell
Signaling Technology). Antibodies were as follows: rabbit anti-phospho-
Fak (pY576/pY577); rabbit anti-Fak, rabbit anti-phospho-Akt (pS473); rabbit
anti-Akt, mouse anti-phospho-Stat3 (pY705); rabbit anti-Stat3, rabbit
anti-phospho-Pdgfr-b (pY751); rabbit anti-Pdgfr-b, mouse anti-phospho-
Fgfr1 (pY653/654); rabbit anti-phospho-Plcg1 (pY783); rabbit anti-phospho-
Cttn (pY421); rabbit anti-Cttn, rabbit anti-Plcg1, rabbit anti-phospho-Shp-2
(pY542); rabbit anti-phospho-Shp-2 (pY580); rabbit anti-Shp-2, rabbit anti-
Gab1, mouse anti-phospho-Erk1/2 (pT202/pY204); and rabbit anti-Erk1/2
(Cell Signaling Technology); rabbit anti-Erk1/2, mouse anti-vinculin, and
mouse anti-tubulin (Sigma-Aldrich); rabbit anti-Fgfr1, mouse anti-Ras GAP
(Santa Cruz Biotechnology); and mouse anti-Grb2 (BD Biosciences). Bead-
conjugated antibodies for phosphotyrosine enrichment were mouse anti-
phosphotyrosine (P-Tyr-100) and rabbit anti-phosphotyrosine (P-Tyr-1000)
(Cell Signaling Technology).
Cell Culture and Ligand Stimulation
NIH/3T3Mus musculus fibroblast adherent cell cultures were purchased from
ATCC. Cells were cultured in DMEM (Gibco), 100 U/mL penicillin (Invitrogen),
and 100 mg/mL streptomycin (Invitrogen) and supplemented with 10%
newborn calf serum (NBCS) (Gibco) at 37C in a humidified incubator with
5% CO2. For the ligand stimulation experiment, cells were serum-starved
overnight in serum-free medium. Cells were stimulated for the indicated time
points with 100 ng/mL of Pdgf-bb, Fgf-2, or Igf-I. Ligands were replenished
every 24 hr for long-term stimulation. All experiments were performed at
80% confluence on Nunc Petri dishes (245 or 150 mm) except for the wound
healing scratch assay, for which 95% confluence was used. Experiments for
cell-based assays were performed in either 24-well plates or 6-well plates.
All cells were tested for mycoplasma with a PCR-based method every third
week.
SILAC
NIH/3T3 cells were cultured in high-glucose DMEM (Biowest) lacking lysine
and arginine supplemented with 10% dialyzed fetal bovine serum (Gibco),
2 mM L-glutamine (Gibco), 100 U/mL penicillin (Invitrogen), and 100 mg/mL
streptomycin (Invitrogen). Three cell populations were obtained: one labeled
with natural variants of the amino acids: light label: Lys0, Arg0 (Sigma), the
second labeled with medium variants of amino acids {L-[2H4]Lys (+4) and
L-[13C6]Arg (+6)} (Lys4, Arg6), and the third labeled with heavy variants of the
amino acids {L-[13C6, 15N2]Lys (+8) and L-[13C6, 15N4]Arg (+10)} (Lys8,
Arg10). Medium and heavy variants of amino acids were purchased from
Cambridge Isotope Laboratories. According to determined protein concentra-
tion via Bradford assay (Bio-Rad), proteins for each SILAC condition were
mixed at 1:1:1 ratio.
Cell Lysis and Western Blots
For proteomic analysis, cells were quickly washed twice with cold 13 PBS
after stimulation. Boiling lysis buffer (6 M guanidium hydrochloride and
25 mM Tris [pH 8]) containing 5 mM tris(2-carboxyethyl)phosphine (TCEP)
and 5.5 mM chloroacetamide (CAA) was added to culture plates. Cells were
then scraped and collected. Following collection, the samples were boiled
at 99C for 10 min, followed by sonication using a tip. Bradford assay (Bio-
Rad, Hercules, CA, USA) was used to determine protein concentration. For
biochemical assays, cells were washed twice with cold 13 PBS after stimula-
tion. Cell extraction was performed in lysis buffer (50 mM Tris HCl [pH 7.6],
150 mM NaCl, and 1% Triton) supplemented with complete mini EDTA-free
protease inhibitor (Roche) and 1mM of sodium fluoride (NaF), b-glycerol phos-
phate, and sodium orthovanadate (Na3PO4). Following centrifugation at
13,0003 g for a least 20min at 4C, the protein concentration was determined
using Bradford assay (Bio-Rad). When needed before stimulation, cells were
preincubated for 30 min with 10 mM U0126 and 10 mM PF-562271 and for
1 hr with 10 mM SHP099 inhibitor. Control cells were preincubated with
DMSO alone. After sample collection, immunoblotting was performed as pre-
viously described (Francavilla et al., 2016). Quantification analysis was per-
formed with ImageJ software, and images were processed by Photoshop
and Illustrator software (CS6 version; Adobe). Each experiment was repeated
at least three times and produced similar results.
Cell Proliferation Assay
Cells were seeded in triplicate on 24-well plates at 4 3 104 cells/well, serum-
starved overnight, and treated for either 72 or 96 hr with 100 ng/mL of Fgf-2,Pdgf-bb, and Igf-I. When needed, cells were treated with 10 mMSHP099 inhib-
itor and 10 mM U0126 for the indicated time point, and control cells were
treated with DMSO alone. Medium with fresh ligands and inhibitor was replen-
ished every 24 hr. At each time point, viable cells were counted with trypan
blue exclusion method, and the ratio to unstimulated cells at time 0 was deter-
mined for each time point as previously described (Francavilla et al., 2016).
Values represent the means ± SEM from at least three independent experi-
ments performed in triplicate.
Wound Healing Scratch Assay
The migratory behavior of NIH/3T3 cells was evaluated using the scratch
(wound healing) assay. Equal numbers of cells were seeded in triplicate on
6-well plates and allowed to reach confluency. Cells were then serum-starved
overnight, and the wound was made by scratching a line across the bottom of
the dish on a confluent cells monolayer. One wound per well was made using a
sterile p-10 pipette tip spanning thewell. Cells were rinsed gently with PBS and
then treated for 24 hr with 100 ng/mL of Pdgf-bb or Fgf-2. When needed before
stimulation, cells were preincubated with 10 mM SHP099 inhibitor for 30 min.
Control cells were preincubated with DMSO alone. Migration of cells was
observed at premarked positions below the wells using a Leica DMI3000
inverted microscope at 53 magnification. Quantification was performed
manually by counting the number of migrating cells within the scratch cross-
sectional area. Values represent themeans ± SEM from at least three indepen-
dent experiments performed in duplicate.
Immunoprecipitation
For pull-downs, stimulation was performed as described earlier and lysis was
performed in the samemanner as for biochemical assays. NIH/3T3 cell lysates
(1 mg per condition) were precleared with anti-rabbit immunoglobulin G (IgG)
(Sigma-Aldrich) supplemented with Protein G-Sepharose beads (Invitrogen)
and inversion rotated for at least 2 hr at 4C. After centrifugation at 1,000 rela-
tive centrifugal force (RCF) for 5 min, cleared samples were incubated with
anti-Pdgfr-b antibody overnight at 4C (1:150 ratio). Protein G-Sepharose
beads were added for 1 hr at 4C, and the immunoprecipitated proteins
were washed three times with ice-cold lysis buffer: once with 50 mM NaCl,
once with 150 mM NaCl, and once with Milli-Q H2O. Proteins were eluted
from beads by boiling in lithium dodecyl sulfate (LDS) sample buffer (Novex).
Immunofluorescence Imaging
For fluorescent microscopy, human Gab1 (transcript variant 1) was gateway
cloned into the destination vector pcDNA4/TO/GFP. Cells were grown on
coverslips and transfected with pcDNA4/TO/GFP-GAB1 using Fugene 6
(Promega) for 12 hr. After stimulation, cells were fixed in 4% formaldehyde
and permeabilized with PBS containing 0.2% Triton X-100 for 5 min. Cover-
slips were mounted with Vectashield mounting medium (Vector Laboratories)
containing the nuclear stain DAPI. Images were acquired with a Leica
DMI6000B wide-field microscope (Leica Microsystems) equipped with an
HC Plan-Apochromatic 633/1.4 oil immersion objective. Image acquisition
and analysis were carried out with LAS X and ImageJ software.
Sample Prep for MS
Lys-C protease (Wako Chemicals, Richmond, VA, USA) at a 1:100 (w/w) ratio
was used to digest proteins to peptides for 2 hr at 37C. Samples were then
diluted with 50 mM ammonium bicarbonate to <2 M guanidinium concentra-
tion, and trypsin was added at 1:50 (w/w) to generate tryptic peptides over-
night at 37C. Following digestion, samples were acidified with trifluoroacetic
acid (TFA, 1% final) and centrifuged to remove debris. Peptides were then
desalted on a C18 sep-pak (Waters, Milford, MA, USA) and stored until further
processing. Following elution with 50% acetonitrile, samples were concen-
trated using a SpeedVac.
Automated Concatenation and Fractionation of Tryptic Peptides
Ultimate 3000 ultra-high performance liguid chromatography (UHPLC) (Dio-
nex, Sunnyvale, CA, USA), in conjunction with high-pH reversed-phase
chromatography, was used to separate and fractionate tryptic peptides. Pep-
tides were separated using a high-pH-compatible 250 3 4.6 mm C18 Waters
BEH X-Bridge peptide separation technology (PST) 3.6 mM or PhenomenexCell Reports 22, 2784–2796, March 6, 2018 2793
Kinetex Evo 2.6 mM (Torrance, CA USA) column with identical dimensions.
Basic conditions were achieved by running buffer C (50 mM ammonium
hydroxide) constantly at 10% (100 mL/min, 5 mM ammonium hydroxide final).
A 60 min fractionation and collection gradient was achieved using buffer A
(Milli-Q H2O) and buffer B (acetonitrile), and fractions were collected at 1 min
intervals and AUTOCON into 10 fractions in a 24-well plate (Movie S1). Running
at a constant 1mL/min, the gradient was increased from 5% to 25%buffer B in
50 min and further increased to 70% buffer B in 5 min, where it was held for
another 5 min. At this point, the fraction collection was stopped. Each fraction
sampled 6 points across the gradient, resulting in a 6-mL volume per fraction.
100 mL were removed from each fraction for proteome analysis, 6 mL of 88%
acetonitrile with 12% TFA was added to each fraction, and samples were
stored.
TiO2 Enrichment of Phosphopeptides
Each fraction was enriched with metal oxide affinity chromatography (MOAC)
enrichment in batch mode by addition of titanium dioxide (TiO2) beads (GL
Sciences, Japan) preincubated with 2,3-dihydroxybenzoic acid (DHB) and
mixed for 20 min at room temperature. Fractions 1–5 and 6–10 were com-
bined, and double-TiO2 enrichment was performed to bring total number of
fractions for phosphoproteome analysis per replicate to 12. TiO2 beads were
collected using centrifugation and washed on C8 StageTips in a 96-well
format. Phosphopeptides were eluted under basic conditions (5% ammonium
hydroxide and 25% acetonitrile) and dried to remove residual acetonitrile.
Phosphopeptides were then washed and loaded onto C18 StageTips in a
96-well format, where they were stored until further analysis by LC-MS/MS.
Phosphotyrosine and pSer or pThr Peptide Enrichment
Phosphotyrosine-containing peptides were enriched using a 1:1 mixture of
bead-conjugated anti-phosphotyrosine antibodies (PTM scan pY100 and
pY1000, Cell Signaling Technology). One vial of each antibody was used for
two samples. Bead-conjugated antibodies were washed 43 in 1 mL of PBS
and resuspended in 3-(N-morpholino) propanesulfonic acid (MOPS) buffer.
Peptides for phosphotyrosine enrichment were eluted from C18 sep-pak with
40% and 60% acetonitrile (ACN). Eluted peptides were concentrated to a
volume under 100 mL using a vacuum concentrator and incubated at 4C
with 1.5 mL of immunoprecipitation buffer (50 mM MOPS [pH 7.2], 10 mM
sodium phosphate, and 50 mMNaCl) overnight. Clarified peptides were sepa-
rated by centrifugation at 10,000 RCF for 5 min at 4C, and supernatants were
transferred to a new tube. Antibodies were thereafter added to the samples
and incubated for 2 hr at 4C. The antibody-peptide complexes were washed
5 times with cold MOPS buffer, 2 times with 50 mMNaCl, 2 times with 150 mM
NaCl, and 1 time with Milli-Q H2O. Supernatants of each wash were preserved
for subsequent TiO2 enrichment. Peptides were eluted from the antibodies
using 300 mL of 0.1% TFA twice and loaded on C18 StageTips, where they
were stored until further analysis by LC-MS/MS.
For phosphorylated serine and threonine (pST) enrichment, supernatant
from pTyr enrichment was acidified using TFA and washed on C18 sep-paks.
Sep-paks were eluted as described earlier, and ACN and TFA were added
to final concentrations of 80% and 5%, respectively. TiO2 beads were added
to the eluate, enriched for phosphopeptides, and prepared for LC-MS/MS
analysis as described earlier. A second round of incubation was performed
on the eluate, resulting in two samples for pST analysis.
Nano-liquid Chromatography and MS Analysis
Thermo Fisher Orbitrap HF (Bremen, Germany) mass spectrometer operating
in positive mode coupled to Easy-nLC 1000 was used in the analysis of all
samples. For phosphoproteomic analysis, all samples were analyzed with
sensitive MS parameters. Spectra were acquired with survey MS scans at
an Orbitrap resolution of 120,000 (full width at half maximum [FWHM]), from
which the top 7 most abundant peaks were selected for higher-energy colli-
sional dissociation (HCD) fragmentation and the resulting fragment spectra
were collected at 60,000MS/MS resolution. For proteome analysis, MS survey
scan resolution of 60,000was used and theHCD spectra were collected for the
top 10 most abundant peaks at a resolution of 30,000. Peptides were sepa-
rated in a 15-cm microbore column (75 mM inner diameter) packed in-house
with 1.9 mM C18 beads (Dr. Maisch, Germany) at 250 nL/min. Identical fast2794 Cell Reports 22, 2784–2796, March 6, 2018gradient was used in the analysis of all samples. Buffer B (80% ACN and
0.1% formic acid) was increased from 5% to 35% in 55 min to 45% in
5 min. This was followed by a quick ramp up to 80% buffer B in 2 min. It
was held there for additional 5 min before declining back down to 5% in
5 min, where it was held for an additional 5 min to re-equilibrate the column.
For single-shot analysisofSILACpTyrandpST,sensitive scanningMSparam-
eterswereusedasdescribedearlier,except that the top10mostabundantpeaks
were selected for HCD fragmentation. In addition, a longer gradientwas used for
single-shot analysis on a similar 15-cmcolumn, consisting of an increase to 25%
buffer B in 110 min followed by an increase to 40%buffer B in 25min. After this,
the column was increased to 80% buffer B in 5 min, where it was held for 5 min,
followed by a ramp down to 5% buffer B for column re-equilibration.
LC-MS/MS Database Search
All files were processed together, and raw data were searched using
MaxQuant v.1.5.3.33 with Andromeda search engine (http://www.maxquant.
org) (Cox and Mann, 2008) against the Mus musculus uniprot database. The
MS/MS spectra were searched with carbamidomethyl as a fixed modification
on cysteine and variable modification oxidation on methionine, protein n-ter-
minus acetylation, and phosphorylation on serine, threonine, and tyrosine,
along with deamidation on asparagine and glutamine. A false discovery rate
(FDR) of 1% was used at the peptide and protein level. Protein quantitation
required minimum of two peptides without modifications.
Phosphoproteomic Analysis
Resulting identified phosphorylation sites (phospho STY(sites).txt table) from
MaxQuant analysis were filtered only for those that were confidently localized
(class I, localization probability R 0.75). Replicates were retained only when
>10,000 high-confident phosphorylation sites were present, resulting in a
minimum of 5 replicates for each condition. Quantile normalization (Figure 1C)
was used to normalize the phosphorylation data (Bolstad et al., 2003). A site
was deemed quantifiable when it was observed a minimum of two times in
at least one condition, resulting in >29,000 total quantifiable sites. The resulting
quantile normalized sites were used for all analysis of phosphorylation data
presented in this publication.
SILAC Analysis
SILAC phosphoproteome samples were analyzed with search parameters
similar to those described earlier, with the addition of SILAC multiplicity indi-
cating a triple SILAC setup. Resulting phosphorylation sites were analyzed in
Perseus v.1.5.2. MaxQuant normalized ratios were used for quantitation.
Phosphorylated serine, threonine, and tyrosine (pSTY) sites were expanded
to differentiate multiple peptide phosphorylation states and filtered only for
those that were confidently localized (class I, localization probabilityR 0.75).
Reverse and contaminant hits were removed from the analysis, and sites
had to be observed for a minimum of 2 of 3 replicates in each of the 3 condi-
tions to be considered for quantitation.
Proteome Analysis
Perseus v.1.5.2.6 was used for analysis of proteomics (Tyanova et al., 2016).
For quantitative analysis of protein abundance changes, label-free quantita-
tion (LFQ) values were employed (Cox et al., 2014), and intensity-based abso-
lute quantification (iBAQ) analysis was used for relative expression analysis.
Significant proteins were determined on log10-transformed LFQ values using
a Student’s t test.
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